Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04553523 · ClinicalTrials.gov registry record · NA

Hydrus® Microstent New Enrollment Post-Approval Study

A NA study of Primary Open Angle Glaucoma, sponsored by Alcon Research.

Recruiting
Registry status
NA
Development phase
545
Enrollment target
20
Study locations

NCT04553523: Recruiting NA study of Primary Open Angle Glaucoma, sponsored by Alcon Research.

NCT04553523 is a NA study of Primary Open Angle Glaucoma that is actively recruiting participants, run by Alcon Research. The registered enrollment target is 545 participants, above the 266-participant average among 19 other Primary Open Angle Glaucoma trials with a reported enrollment target (105% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04553523, a NA study of Primary Open Angle Glaucoma, is actively recruiting participants, sponsored by Alcon Research.

RECRUITING
Registry status
NA
Development phase
545 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this post-approval study is to evaluate the rate of Hydrus Microstent malposition and associated clinical sequelae occurring within 24 months post-operation. Qualified subjects will undergo uncomplicated cataract surgery with placement of a monofocal intraocular lens (IOL), followed by implantation of the Hydrus Microstent.

Primary Outcome

The position of the implant will be assessed visually intraoperatively and at each postoperative follow-up visit. Examples of clinically significant device malposition associated with clinical sequelae as listed in the protocol include secondary surgical intervention to modify device position or to remove the device (explantation), corneal endothelial touch by device, iris touch by the device associated with intraocular inflammation, pigment dispersion or other sequelae, central endothelial cell

Interventions

  • DEVICE Hydrus Microstent
  • PROCEDURE Cataract surgery
  • DEVICE Monofocal IOL

Study Locations (20)

Texas

  • Texan Eye / Keystone Research - Austin
  • Glaucoma Associates Of Texas - Dallas
  • El Paso Eye Surgeons - El Paso
  • Texas Eye Research Center - Hurst

Ohio

  • Cleveland Eye Clinic - Brecksville
  • Cincinnati Eye Institute - Cincinnati
  • Cincinnati Eye / Apex Eye - Mason

California

  • Coastal Vision - Irvine
  • Sacramento Eye Consultants - Sacramento

Missouri

  • Midwest Vision Research Foundation - Chesterfield
  • Moyes Eye Center - Kansas City

Colorado

  • Eye Center of Northern Colorado - Loveland

Iowa

  • Jones Eye Center PC - Sioux City

Kansas

  • Stiles Eyecare Excellence Cataracts and Glaucoma - Overland Park

Maryland

  • Visionary Eye Doctors - Rockville

Trial Details

FieldValue
Enrollment Target 545 participants
Start Date 2020-08-25
Est. Completion 2028-06
Phase NA
Alcon Research

275 total trials

What NCT04553523 shows while recruiting

NCT04553523 is an interventional study that assigns participants to a tested intervention. The registered 545 participants enrollment target is mid-sized for trials with a published cap, above the 266-participant average among 19 other Primary Open Angle Glaucoma trials with a reported enrollment target (105% higher).

The record links to 1 condition, with Primary Open Angle Glaucoma appearing as the primary indexed condition, and to 3 interventions - of which Hydrus Microstent is the first listed.

NCT04553523 names 20 study sites across 13 states, led by Texas, Ohio, California.

Frequently Asked Questions

What is clinical trial NCT04553523 about?

NCT04553523 is a clinical study titled "Hydrus® Microstent New Enrollment Post-Approval Study". The purpose of this post-approval study is to evaluate the rate of Hydrus Microstent malposition and associated clinical sequelae occurring within 24 months post-operation. Qualified subjects will undergo uncomplicated cataract surgery with placement of a monofocal intraocular lens (IOL), followed b...

What is the current status of trial NCT04553523?

This trial is currently recruiting. It is a NA study. The enrollment target is 545 participants. The study started on 2020-08-25. Estimated completion is 2028-06.

What conditions does trial NCT04553523 study?

This clinical trial studies the following conditions: Primary Open Angle Glaucoma.

What interventions are being tested in trial NCT04553523?

The interventions under investigation include: Hydrus Microstent (DEVICE), Cataract surgery (PROCEDURE), Monofocal IOL (DEVICE).

Who is sponsoring clinical trial NCT04553523?

This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04553523 being conducted?

This trial has 20 study locations across California, Colorado, Iowa, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Primary Open Angle Glaucoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04553523's enrollment target sits among peer trials

545 2nd of 19 the highest of 19 other Primary Open Angle Glaucoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Primary Open Angle Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03572374 · 546 participants · NA

    Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job

  • NCT05937685 · 546 participants · NA

    Reducing Blood Pressure in Patients With High Cardiovascular Risk

  • NCT06416150 · 546 participants · NA

    Reducing Urban Cervical Cancer Disparities

  • NCT06850922 · 546 participants · Phase 1

    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04553523, the US trial registry maintained by the National Library of Medicine. NCT04553523 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.